Resverlogix Corp.
Locations:- Calgary, Alberta
Headcount: 35 employees
Industries:
- Biotechnology
- Healthcare Facility
Organization Profile
Resverlogix is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet medical needs. These vital therapies are focused on
addressing the burden of Atherosclerosis and many other important diseases
including Acute Coronary Syndrome, Alzheimer’s disease, Peripheral Artery
Disease and Autoimmune diseases. The NexVas™ Plaque Regression program is the
Company’s primary focus which is to develop novel small molecules that enhance
ApoA-I production and thereby raise high density lipoprotein (HDL) for the
treatment of Atherosclerosis. Lead drug RVX-208 is currently in two Phase 2b
Clinical Trials led by the Cleveland Clinic. Resverlogix’s common shares trade
on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.
Contact Information
Kenneth Lebioda
Senior VP Business & Corporate Development
Tel: 403-254-9252 ex. 233
Fax: 403-256-8495
brad@resverlogix.com
Sarah Zapotichny
Director of Investor Relations
Tel: 403-254-9252 ex. 234
Fax: 403-256-8495
sarah@resverlogix.com
Market Performance
Latest News Releases
